AKRO•benzinga•
Akero Therapeutics Presents Week 96 Results From Phase 2b SYMMETRY Clinical Trial Of Efruxifermin In Patients With Compensated Cirrhosis Caused By MASH Showing Fibrosis Improvement Without Worsening Of MASH At EASL Congress 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 9, 2025 by benzinga